T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
626
Pebblebrook Hotel Trust
PEB
$2.05B
| $54.5M | 0.01% |
3,754,179
-5,070,672
| -57% | -$91.2M |
|
627
EPAM Systems
EPAM
$5.24B
| $54.5M | 0.01% |
150,380
-28,360
| -16% | -$10.8M |
|
628
Novanta
NOVT
$6.33B
| $54M | 0.01% |
467,320
-1,620,122
| -78% | -$221M |
|
|
BHVN
629
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
| $53.9M | 0.01% |
356,257
-165,323
| -32% | -$24.5M |
|
|
LTHM
630
DELISTED
Livent Corporation
LTHM
| $53.4M | 0.01% |
1,742,535
+408,249
| +31% | +$11.4M |
|
631
Cytokinetics
CYTK
$10.2B
| $53M | 0.01% |
1,093,447
+595,708
| +120% | +$28.7M |
|
632
Watsco Inc
WSO
$12.9B
| $52.5M | 0.01% |
203,952
-64,868
| -24% | -$17.6M |
|
633
Immuneering
IMRX
$336M
| $52.5M | 0.01% |
3,663,492
-479,337
| -12% | -$3.81M |
|
634
Blue Owl Capital
OWL
$19.7B
| $52.4M | 0.01% |
5,672,724
+305,780
| +6% | +$3.4M |
|
635
Delta Air Lines
DAL
$60B
| $52.3M | 0.01% |
1,863,984
+251,480
| +16% | +$7.99M |
|
|
CHX
636
DELISTED
ChampionX
CHX
| $52.2M | 0.01% |
2,668,246
-4,536,737
| -63% | -$93.6M |
|
637
Globus Medical
GMED
$11.5B
| $51.9M | 0.01% |
871,758
+5,267
| +0.6% | +$317K |
|
638
BioMarin Pharmaceuticals
BMRN
$13.3B
| $51.9M | 0.01% |
611,707
+86,888
| +17% | +$7.74M |
|
|
DICE
639
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
| $51.8M | 0.01% |
2,553,457
+138,833
| +6% | +$2.53M |
|
|
DHR.PRB
640
DELISTED
Danaher Corporation 5.00% Mandatory Convertible Preferred Stock, Series B
DHR.PRB
| – | – |
-38,279
| Closed | -$54.3M |
|
641
Clean Harbors
CLH
$16.9B
| $51M | 0.01% |
463,901
+45,140
| +11% | +$4.83M |
|
|
IGMS
642
DELISTED
IGM Biosciences
IGMS
| $50.4M | 0.01% |
2,217,766
-405,107
| -15% | -$8.18M |
|
643
Iridium Communications
IRDM
$5.27B
| $50.3M | 0.01% |
1,133,727
+24,100
| +2% | +$1.04M |
|
644
Phillips 66
PSX
$92.8B
| $50.3M | 0.01% |
622,799
-337
| -0.1% | -$28.7K |
|
645
Merit Medical Systems
MMSI
$5.4B
| $50.1M | 0.01% |
886,190
+2,344
| +0.3% | +$135K |
|
646
QuidelOrtho
QDEL
$1.03B
| $49.8M | 0.01% |
697,068
-6,948,213
| -91% | -$622M |
|
|
AKRO
647
DELISTED
Akero Therapeutics
AKRO
| $49.8M | 0.01% |
1,462,424
+1,007,122
| +221% | +$15.4M |
|
648
Wendy's
WEN
$1.65B
| $49.7M | 0.01% |
2,661,751
+23,127
| +0.9% | +$466K |
|
649
Public Service Enterprise Group
PEG
$37.8B
| $49.7M | 0.01% |
883,241
-1,273,548
| -59% | -$82M |
|
650
Newmont
NEM
$120B
| $49.5M | 0.01% |
1,178,531
+152,879
| +15% | +$7.14M |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.